Evozyne has closed an $81 million Series B investment round that will fund the biotech’s generative AI-powered drug discovery platform and product development.
“In its first three years, Evozyne proved it could deliver novel, high-performance proteins that solve critical problems in healthcare and sustainability. Our next three years will be tightly focused on maximising our generative AI platform for drug development and carbon capture, while we develop a portfolio of gene editors and enzymes that modulate immune response,” said Mike Gamson, Evozyne’s CEO.
The funding follows a successful collaboration with NVIDIA earlier this year, in which the companies developed an AI model that can be used to design therapeutic proteins.
The approach, presented by NVIDIA at the JP Morgan Healthcare Conference, greatly increases the number and quality of synthetic protein designs, which opens up the possibility to design new therapeutics and reduce development time for new treatments.
Find out more about generative AI in drug discovery in a webinar on 12 October.
